ERBB2 and breast cancer: The multicenter ZEPHIR study proposed the use of [89Zr]trastuzumab (HER2-PET/CT) to detect lesions in patients with HER2-positive metastatic BC and showed that pretreatment imaging using HER2-PET/CT is a viable method for examining interlesion heterogeneity in advanced disease stages.